## Abstract This study investigated whether domperidone could improve gastrointestinal symptoms in patients with Parkinson's disease who were receiving levodopa therapy. A total of 11 patients were studied. Following a baseline gastric emptying test, patients were treated with a starting dose of do
Gastrointestinal symptoms in Parkinson's disease
β Scribed by L. L. Edwards; Dr. R. F. Pfeiffer; E. M. M. Quigley; Ruth Hofman; Mary Balluff
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 571 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
β¦ Synopsis
We have investigated the prevalence of gastrointestinal (GI) symptoms in 98 individuals with Parkinson's disease (PD) and in a control group of 50. Seventy-nine of those with PD were being treated with dopaminergic medications and 19 were untreated. Those symptoms occurring more frequently in PD patients than in controls included abnormal salivation, dysphagia, nausea, constipation, and defecatory dysfunction. Except for defecatory dysfunction, symptoms did not correlate with treatment but instead correlated with disease severity. This suggests that the GI symptoms of PD reflect direct involvement in the GI tract by the primary disease process.
π SIMILAR VOLUMES
## Abstract Visual symptoms are common in PD and PD dementia and include difficulty reading, double vision, illusions, feelings of presence and passage, and complex visual hallucinations. Despite the established prognostic implications of complex visual hallucinations, the interaction between cogni
## Abstract In a recent study we identified abnormal salivation, dysphagia, nausea, constipation, and defecatory dysfunction as those gastrointestinal (GI) symptoms associated with Parkinson disease (PD) and characterized their relationship to PD severity and therapy. In this study, we reβevaluated
## Abstract Neuropsychiatric symptoms are common in Parkinson's disease, even at the earliest stages, and have important consequences for quality of life and daily functioning, are associated with increased carer burden and increased risk for nursing home admission. In addition to cognitive impairm
In their excellent review of neuropsychiatric problems in Parkinson's disease (PD), 1 the authors made one small error but more importantly raised an interesting question about drug trials. Also, as they wrote their article, both melperone (personal communication) and pimavanserin, 2 subjected to ra